<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Front-loaded systemic eradication with response-guided personalization (FSC-RGP) - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-21</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-21</p>
                <p><strong>Name:</strong> Front-loaded systemic eradication with response-guided personalization (FSC-RGP)</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why neoadjuvant-plus-adjuvant immunotherapy improves melanoma outcomes compared to adjuvant-only immunotherapy, based on the following results.</p>
                <p><strong>Description:</strong> Administering immune checkpoint blockade before surgery 'front-loads' systemic control by treating occult micrometastatic disease at first contact while tumor antigens are abundant in situ. This timing induces broader and more durable antitumor immunity than post-operative initiation alone, reduces early perioperative events, and converts depth of preoperative tumor kill (pathologic response) into a mechanistic surrogate for systemic control. The surrogate then enables response-guided tailoring of post-operative therapy (de-escalation for major responders, escalation for non-responders) to optimize outcomes and toxicity.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Law 2</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Across external cohorts implementing high-quality INMC pathology, MPR after neoadjuvant PD-1–based therapy will predict ≥90% 2-year RFS, enabling safe omission of TLND/adjuvant in most MPR patients.</li>
                <li>Short-course neoadjuvant PD-1 induces early systemic changes (e.g., ctDNA clearance, blood immune 'response signature') that enrich for MPR and correlate with improved EFS.</li>
                <li>Neoadjuvant ipi1+nivo3 induction followed by PD-1 adjuvant will achieve superior EFS with fewer grade ≥3 irAEs compared with prolonged adjuvant dual ICI.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>A strategy of neoadjuvant dual ICI with complete omission of adjuvant therapy in MPR patients will be non-inferior in EFS to standard adjuvant PD-1, with substantially reduced toxicity and cost.</li>
                <li>Adaptive perioperative therapy (escalate from PD-1 to dual ICI after one neoadjuvant dose if blood response signature fails) will improve MPR without materially increasing ≥grade 3 irAEs.</li>
                <li>Combining neoadjuvant PD-1 with intratumoral dendritic cell agonism will shift partial pathologic responders into MPR and raise 2-year RFS in that subgroup from ~64% to ≥80%.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>A randomized study showing no EFS advantage of neoadjuvant+adjuvant PD-1 over adjuvant-only PD-1 with matched exposure would refute the front-loading claim.</li>
                <li>Prospective data demonstrating that MPR after neoadjuvant immunotherapy does not stratify 2-year RFS would undermine response-guided personalization.</li>
                <li>A trial proving that optimized ipi1+nivo3 does not reduce grade ≥3 irAEs compared with ipi3+nivo1 would challenge the safety-tuning principle.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Exact optimal duration and composition of adjuvant therapy after neoadjuvant MPR (PD-1 monotherapy vs none) remain undefined in randomized data. </li>
    <li>Determinants of preoperative progression under neoadjuvant PD-1 (biology vs kinetics) are incompletely characterized. <a href="../results/extraction-result-19.html#e19.3" class="evidence-link">[e19.3]</a> <a href="../results/extraction-result-19.html#e19.2" class="evidence-link">[e19.2]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>